Contribution of HBV and HCV infection in mortality of B cell non-Hodgkin’s  lymphoma subjects

Myagmarjav B; Anir E; Delgerbat B; Khishigjargal B; Myadagsuren S; Erdenetsogt D; Dahgwahdorj Ya; Davaadorj D; Naranjargal D

Return

Contribution of HBV and HCV infection in mortality of B cell non-Hodgkin’s lymphoma subjects

VernacularTitle:В- эсийн Ходжкины бус лимфома оношлогдсоноос хойших эрт нас баралтад хепатитын В, С вирүсийн нөлөө
Author: Myagmarjav B ¹ ; Anir E ¹ ; Delgerbat B ¹ ; Khishigjargal B ² ; Myadagsuren S ² ; Erdenetsogt D ³ ; Dahgwahdorj Ya ¹ ; Davaadorj D ³ ; Naranjargal D ¹
Author Information

1. Liver Center, Ulaanbaatar, Mongolia
2. First Central Hospital of Mongolia
3. Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
Publication Type:Journal Article
Keywords: Ann-Arbor stage; anti-HCV; HBsAg; B-non-Hodgkin’s Lymphoma, survival rate
From:Mongolian Medical Sciences 2020;191(1):19-25
CountryMongolia
Language:Mongolian
Abstract: Background:The correlation between hepatitis B, C viruses (HBV, HCV) and B cell non-Hodgkin’s Lymphoma (B-NHL) and reducing mortality have been studied extensively worldwide
Objective:In this study, we aimed to determine the prevalence of HBsAg and anti-HCV positive cases among B-NHL patients and its influence on the survival rate of these patients (on ≤12 months).
Materials and Methods:We have done a retrospective analysis on patients who aged over 20 years and newly diagnosed at the Hematology Center of the First State Hospital between 2015-2018. The patients’ information was collected according the study ethics. We divided the patients into 2 groups, survival rate less than 12 months (≤12 months) and survival rate more than 13 months (≥13 months), and compared them regarding age, gender, seroprevalence, and Ann-Arbor stage.
Results:Overall, 226 patients (107 males and 119 females with average 54.4) were enrolled in the study. There were 15% HBsAg positive and 41,6% anti-HCV positive cases, while Baatarkhuu et al. (2005) reported (11.8%, 15.6%; p=0.160, p<0.00001) and Bekhbold et al. (2013) reported (11.1%, 10.6%; p=0.055, p<0.00001) in apparently healthy population. Moreover, anti-HCV positive cases among B-NHL patients were higher (p<0.00001) than those (27%) among hepatocellular carcinoma (HCC) patients and same (p=0.404) with those (39%) among liver cirrhosis patients in Mongolia (Bolormaa et al., 2009). Furthermore, 72.0% of all subjects in III-IV stages was accounted for HBsAg, anti-HCV positive group which had ≤12 months, while 52.1% of them was accounted for HBsAg, anti-HCV positive group which had ≥13 months and was statistical significantly lower (p=0.02).
Conclusion:Anti-HCV and HBsAg positive cases might contribute to survival rate with the B-NHL patients diagnosed at the III-IV stages. HCV prevalence among B-NHL subjects was significantly higher than that among the general population prevalence and was same with anti-HCV positive prevalence among the HCC.
Full text:2020-191(1)-19-25.pdf